$0.20
(Market cap
$1,025 Mln
Revenue (TTM)
$428 Mln
P/E Ratio
--
P/B Ratio
6.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-21 Mln
-
ROE
-0.1 %
-
ROCE
-5.1 %
-
Industry P/E
--
-
EV/EBITDA
161.2
-
Debt to Equity
0.5
-
Book Value
$10.6
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
29,288,739
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GeneDx Holdings
| -73.3 | -47.6 | -58.7 | -47.5 | 59.5 | -39.1 | -- |
|
BSE Sensex*
| -8.1 | 5.0 | -6.9 | -3.5 | 8.4 | 9.7 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
GeneDx Holdings
| 69.2 | 2,620.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 |
|
BSE Sensex
| 9.1 | 8.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
GeneDx Holdings
|
34.7 | 1,024.5 | 427.5 | -21.0 | -4.4 | -7.6 | -- | 6.5 |
| 14.2 | 3,350.2 | 3,125.0 | -262.7 | 0.9 | -313.2 | -- | 20.5 | |
| 424.6 | 5,675.3 | 2,540.6 | 259.8 | 13.7 | 27 | 23.4 | 6.7 | |
| 105.0 | 10,431.8 | 6,066.4 | 609.2 | 17.9 | 16.2 | 18 | 4.2 | |
| 26.9 | 6,084.1 | 2,347.6 | 128.4 | 4.5 | 25.2 | 51.6 | 11.6 | |
| 20.5 | 3,344.7 | 5,667.2 | 206.2 | 5.9 | 15.2 | 16.6 | 2.5 | |
| 58.6 | 4,619.6 | 2,040.2 | -18.7 | 5.0 | -1.9 | -- | 4.2 | |
| 15.8 | 4,371.5 | 1,163.6 | 78.0 | 26.1 | 15.4 | 37.4 | 7.2 | |
| 194.5 | 16,099.9 | 21,455.0 | 1,703.0 | 16.4 | 17.1 | 9.7 | 3.3 | |
| 175.9 | 10,283.5 | 5,274.0 | 363.4 | 9.1 | 16.2 | 28.7 | 4.5 |
Shareholding Pattern
View DetailsAbout GeneDx Holdings
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also... develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut. Address: North Tower, Stamford, CT, United States, 06902 Read more
-
President, CEO & Director
Ms. Katherine A. Stueland
-
President, CEO & Director
Ms. Katherine A. Stueland
-
Headquarters
Stamford, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for GeneDx Holdings
What is the current share price of GeneDx Holdings Corp Today?
The share price of GeneDx Holdings Corp is $34.71 (NASDAQ) as of 06-May-2026 16:16 EDT. GeneDx Holdings Corp has given a return of 59.53% in the last 3 years.
What is the current PB & PE ratio of GeneDx Holdings Corp?
Since, TTM earnings of GeneDx Holdings Corp is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-179.43
|
12.24
|
|
2024
|
-39.69
|
8.46
|
|
2023
|
-0.38
|
0.29
|
|
2022
|
0.00
|
0.01
|
|
2021
|
-0.05
|
0.03
|
What is the 52 Week High and Low of GeneDx Holdings Corp?
The 52-week high and low of GeneDx Holdings Corp are Rs 170.87 and Rs 32.21 as of 07-May-2026.
What is the market cap of GeneDx Holdings Corp?
GeneDx Holdings Corp has a market capitalisation of $ 1,025 Mln as on 06-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in GeneDx Holdings Corp?
Before investing in GeneDx Holdings Corp, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.